Printer Friendly

United Kingdom : High Yield Advancements Enables Therapeutic Solutions through Mammalian Cell Cultures.

As healthcare needs increase, the demand for less expensive and effective solutions is rising, pushing novel production hosts such as mammalian expression systems to advance. Mammalian cell culture technologies are a dominant production system, enabling the development of high value biopharmaceutical products. As a result, mammalian expression systems are playing a significant role in the manufacturing of therapeutic proteins, vaccines as well as biosimilars, biosuperiors and biobetters.

Analysis from Frost & Sullivan, Trends in Mammalian Cell Cultures (http://bit.ly/1W3sPuS), finds Chinese Hamster Ovary (CHO) cell lines will dominate the industry for the next five years, although efforts to modify CHO cell lines for higher yield will continue. Meanwhile, the soaring costs of sophisticated cell line platforms will pave the way for the use of disposable bags as well as single-use technologies for media and process development.

The benefits of mammalian expression systems are manifold and include improved protein folding as well as modification capabilities at the post-translation and product assembly stages, said TechVision Senior Research Analyst Madhumitha Rangesa. The emergence of designer mammalian cell lines will further boost, yield and accelerate therapeutic production.

However, adoption will remain slow as the costs of converting processes for work on new cell lines are steep. Another challenge is the complexity in handling mammalian cell lines, with bioreactors and fermentation processes taking close to three weeks in certain cases. Nevertheless, the initiation of disposable bioreactors and designer cell lines will lighten these shortcomings.

To discourage competition from plant-based expression systems, industry participants must build superior cell lines and new technology platforms with large-scale manufacturing capabilities, suggested Rangesa. Recognizing this, biopharmaceutical companies are outsourcing production processes to devote greater resources to innovation.

Creating solutions capable of catering to the multi-dimensionality of the industry will revitalize product lines and push mammalian cell culture to a dominant position in biopharmaceutical invention.

Trends in Mammalian Cell Cultures, a part of the TechVision (http://ww2.frost.com/research/technology/health-wellness) subscription, brings out the emerging trends in mammalian cell culture systems on a global scale through a detailed description of technology capability, value chain, drivers, restraints, challenges and technology trends evaluated following extensive interviews with market participants. The study offers an assessment of technology adoption and development by region, demand side analysis, recommendations for technology/product/services developers, and technology management strategies. Further, it provides an evaluation of scenario modeling and emerging opportunities as well as technology management strategies and a technology application roadmap. The research also covers key patents from global participants and offers a detailed list of important contacts in the field.

TechVision is an international technology analysis business that produces a variety of technical news alerts, newsletters, and research services.

[c] 2015 Al Bawaba (Albawaba.com) Provided by SyndiGate Media Inc. ( Syndigate.info ).

COPYRIGHT 2015 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2015 Gale, Cengage Learning. All rights reserved.

 
Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Date:Oct 22, 2015
Words:458
Previous Article:United Kingdom : Frost & Sullivan Awards Asurion for Consistently Raising the Bar with Innovations in the North American Retail Product Protection...
Next Article:United Kingdom : Frost & Sullivan Acknowledges the Superior Value Offered by SpiceCSM s Enterprise-grade iPaaS Solution.
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters